International: +1-347-960-6455
Hyperinsulinemia Therapeutics - Pipeline Analysis 2018

Hyperinsulinemia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10031 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Gastroenterology
Select License Type

Hyperinsulinemia is a medical condition which is characterized by increased amount of insulin in blood. The primary cause of the disease is insulin resistance, which can also result in the development of type 2 diabetes. Insulinoma and nesidioblastosis are some other causes of hyperinsulinemia. Major symptoms of the disease are intense hunger, concentration difficulties, fatigue and obesity. People who have higher triglyceride and uric acid level, obesity, type 2 diabetes and hypertension are at a higher risk of developing hyperinsulinemia.

Hanmi Pharmaceutical Co. Ltd. is currently developing HM15136, a long-acting glucagon analog, by using their LAPSCOVERY technology platform for the treatment of congenital hyperinsulinism. Moreover, Zealand Pharma A/S, and Heptares Therapeutics Ltd. are some other major companies involved in the development of therapeutic agents for the treatment of hyperinsulinemia.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.